Despite the emergence of multiple anti‐HER2 regimens, particularly anthracycline‐free neoadjuvant or adjuvant treatments, patients with HER2‐positive breast cancer continue to confront the reality of recurrence, metastasis, or disease progression. This evidence concerns the gene ERBB2 and breast cancer.